Mid-stage angioedema hit sends Kalvista though the roof

Interim phase II data on Kalvista’s on-demand therapy for hereditary angioedema attacks suggest that KVD900 is an effective means of managing this condition. As an oral kallikrein inhibitor, KVD900 has a major advantage over current therapies in this setting, all of which are subcutaneously injected or intravenous.